Retour aux projets

16639.1 PFLS-LS

Assessment of a drug candidate for the treatment of two rare orphan diseases: Morquio type B disease and GM1 gangliosidosis

Résumé

Assessment of a drug candidate for the treatment of two rare orphan diseases: Morquio type B disease and GM1 gangliosidosis

Textes supplémentaires

Abstract

Morquio type B disease and GM1 gangliosidosis are two rare orphan genetic disorders caused by mutated forms of the enzyme beta-galactosidase. A selective beta-galactosidase inhibitor was identified as a potential rescuer of the mutated enzyme as it helps the folding of the enzyme in vitro. The current project proposes to synthesize this potent drug with improved routing, to measure its efficacy on patient cells and to assess its in vivo bioavailability.

Participants

Julie Charollais-Thoenig

Wirtschaftspartner

charollais@dorphan.com

Dorphan SA CHE-407.871.618 Julie Charollais-Thoenig Chemin de l'Eglise 7 1066 Epalinges VD CH

Roger Marti

Kontaktperson

roger.marti@hefr.ch

HEIA-FR Haute Ecole d'ingénierie et d'archi de Fribourg Roger Marti Boulevard de Pérolles 80 1700 Fribourg FR CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2014-07-31
Date de fin
2015-11-30
Coûts totaux approuvés
CHF 156225.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T115 Medical technology 100.0%